VAV1 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL162855	1.00	2/20
SCHEMBL8750573	1.00	2/20
SCHEMBL2411275	0.89	2/20
SCHEMBL18399995	0.89	2/20
SCHEMBL295345	0.88	2/20
SCHEMBL1568997	0.88	2/20
SCHEMBL3211990	0.88	2/20
SCHEMBL11125248	0.86	2/20
SCHEMBL11456837	0.86	2/20
SCHEMBL2413503	0.84	2/20
SCHEMBL18399991	0.84	2/20
SCHEMBL2410891	0.84	2/20
SCHEMBL15423117	0.84	2/20
SCHEMBL16922840	0.84	2/20
SCHEMBL18629102	0.84	2/20
SCHEMBL20438842	0.84	2/20
SCHEMBL9306	0.80	2/20
Phorbol Myristate Acetate (SCHEMBL115567)	0.80	2/20
SCHEMBL1893793	0.80	2/20
SCHEMBL3692272	0.80	2/20

Clinical trials — most relevant to VAV1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Use of Selective JAK Inhibitor in ILD and Skin Tightness of Systemic Sclerosis Versus MMF	PHASE3	COMPLETED
Combination Therapy (Mirdametinib and Sirolimus) for RAS Mutated Relapsed Refractory Multiple Myeloma	PHASE1/PHASE2	SUSPENDED
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia	PHASE2	COMPLETED
SUTENT (SUNITINIB, SU11248)in Patients With Recurrent or Progressive Glioblastoma Multiforme	PHASE2	UNKNOWN
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia	PHASE2	ACTIVE_NOT_RECRUITING
Study in Adult Ph-positive ALL	PHASE2	UNKNOWN
Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation	PHASE2	COMPLETED
Leniolisib for Immune Dysregulation in PIDs	PHASE2	ACTIVE_NOT_RECRUITING
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
New Individualized Therapy Trial for Metastatic Colorectal Cancer	PHASE1/PHASE2	COMPLETED
FAK Inhibitor in Patients With Advanced Solid Tumors	PHASE1	NOT_YET_RECRUITING
Nilotinib in Huntington's Disease	PHASE1	UNKNOWN
Obinutuzumab in Combination With Venetoclax in Previously Untreated Follicular Lymphoma Patients	PHASE1	COMPLETED
Interleukin-2 Treatment for Wiskott-Aldrich Syndrome	PHASE1	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
C-X-C Chemokine Receptor 4 in Chronic Lymphocytic Leukemia	nan	UNKNOWN
Study of the Pathophysiological Mechanisms Involved in Bleeding Events	nan	COMPLETED
Ruxolitinib in Patients With Myelofibrosis	nan	UNKNOWN
Interest of PHARMaceutical Conciliation to Understand Drug Interactions, Phytotherapy, and Targeted Therapies in Chronic Myeloid Leukemia	nan	RECRUITING
Ibrutinib Adapted to Response in Patients With CLL	nan	UNKNOWN
Molecular Disease Profile of Hematological Malignancies	nan	UNKNOWN
ADRB3, ROCK2 and GEF Levels in Overactive Bladder Patients	nan	COMPLETED
NCF Gene & TNFSF4 in SLE Patients	nan	UNKNOWN
Cardiopulmonary Exercise Testing to Evaluate Pulmonary AVMs	nan	COMPLETED
Combination of JAK2 Inhibitor and Erythropoiesis-stimulating Agent in Myelofibrosis	nan	COMPLETED
Liquid Biopsies for Detecting Somatic Mutations in Sporadic Cerebral Arteriovenous Malformations.	nan	NOT_YET_RECRUITING
Prospective Validation of a DNA Damage Repair-Hippo Pathway Signature in Patients With Advanced Gastric Cancer	nan	UNKNOWN
Pilot Trial of Sirolimus/MEC in High Risk Acute Myelogenous Leukemia (AML)	nan	COMPLETED
Prospective Monocentric Clinical-biological Database	nan	RECRUITING

Related proteins — ESM-2 sequence neighbours (a VAV1 binder may also engage these)

Protein	Name	Similarity
Q08DN7	—	1.000	Q08DN7 →
P54100	—	1.000	P54100 →
Q9R0C8	—	1.000	Q9R0C8 →
P27870	—	0.997	P27870 →
Q9UKW4	—	0.990	Q9UKW4 →
P52735	—	0.982	P52735 →
Q62245	—	0.978	Q62245 →
Q60992	—	0.975	Q60992 →
Q7Z6J4	—	0.975	Q7Z6J4 →
NCK1	SH2/SH3 adapter protein NCK1	0.973	landscape →
Q9TTY2	—	0.972	Q9TTY2 →
Q07139	—	0.972	Q07139 →
SOS1	Son of sevenless homolog 1	0.972	landscape →
Q6P0D7	—	0.972	Q6P0D7 →
Q02384	—	0.971	Q02384 →
MAP4K5	Mitogen-activated protein kinase kinase kinase kinase 5	0.970	landscape →
Q8AVG0	—	0.970	Q8AVG0 →
P09760	—	0.970	P09760 →
Q8BY35	—	0.970	Q8BY35 →
Q9H8V3	—	0.969	Q9H8V3 →
O55033	—	0.968	O55033 →
Q91V57	—	0.968	Q91V57 →
Q6DCZ7	—	0.967	Q6DCZ7 →
A7MBL8	—	0.967	A7MBL8 →
Q5U4T3	—	0.967	Q5U4T3 →
Q9UN19	—	0.967	Q9UN19 →
Q8BWW9	—	0.966	Q8BWW9 →
PTPN4	Tyrosine-protein phosphatase non-receptor type 4	0.966	landscape →
O43639	—	0.966	O43639 →
P70451	—	0.966	P70451 →